Intense P53 Staining is a Valuable Prognostic Indicator for Poor Prognosis in Medulloblastoma/central Nervous System Primitive Neuroectodermal Tumors (original) (raw)

References

  1. Gurney JG, Davis S, Severson RK, Fang J, Ross JA, Robison LL: Trends in cancer incidence among children in the US. Cancer 78: 532–541, 1996
    Google Scholar
  2. Evans AE, Jenkin DT, Sposto R, Ortega JA, Wilson CB, Wara W, Ertel IJ, Kramer S, Chang CH, Leikin SL, Hammond GD: The treatment of medulloblastoma: results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 72: 572–582, 1990
    Google Scholar
  3. Tait DM, Thornton-Jones H, Bloom HJG, Lemerle J, Morris-Jones P: Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the international society of paediatric oncology (SIOP I). Europ J Cancer 26: 464–469, 1990
    Google Scholar
  4. Krischer JP, Ragab AH, Kun L, Kim TH, Laurent JP, Boyett JM, Cornell CJ, Link M, Luthy AR, Camitta B: Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma: a Pediatric Oncology Group Study. J Neurosurg 74: 905–909, 1991
    Google Scholar
  5. Packer RJ, Sutton NL, Angio G. Evans AE, Schut L: Management of children with primitive neuroectodermal tumors of the posterior fossa/medulloblastoma. Pediat Neurosci 12: 272–282, 1985-1986
    Google Scholar
  6. Mulhern RK, Kepner JL, Thomas PR, Armstrong TF, Friedman HS, Kun LE: Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: a Pediatric Oncology Group Study. J Clin Oncol 16: 1723–1728, 1998
    Google Scholar
  7. Merchant TE, Wang M, Haida T, Lindsley KL, Finlay J, Dunkel IJ, Rosenblum MK, Leibel SA: Medulloblastoma: long-term results for patients treated with definitive radiation therapy during the computed tomography era. Internat J Rad Oncol Biolog Phys 36: 29–35, 1996
    Google Scholar
  8. Jin Y, Kayser S, Kemp BL, Ordonez NG, Tucker SL, Clayman GL, Goepfert H, Luna MA, Batsakis GJ, El-Naggar AK: The prognostic significance of the biomarkers p21 (WAF1/CIP1), p53, and bcl-2 in laryngeal sqamous cell carcinoma. Cancer 82: 2159–2165, 1998
    Google Scholar
  9. Popov Z, Hoznek A, Colombel M, Bastuji-Garin S, Lefrere-Belda M, Bellot J, Abbor CC, Mazerolles C, Chopin DK: The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Cancer 80: 1472–1481, 1997
    Google Scholar
  10. Miralbell R, Tolnay M, Bierl S: Pediatric medulloblasoma: prognostic value of p53, bcl-2, Mib-1, and microvessel density. J Neuro-Oncol 45: 103–110, 1999
    Google Scholar
  11. Jaros E, Lunec J, Perry RH, Kelly PJ, Pearson ADJ: p53 protein overexpression identifies a group of central primitive neuroectodermal tumours with poor prognosis. Br J Cancer 68: 801–807, 1993
    Google Scholar
  12. Gerdes J, Lemke H, Baisch H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immun 133: 1710–1715, 1984
    Google Scholar
  13. Hall PA, Levison DA, Woods AL: Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 162: 285–294, 1990
    Google Scholar
  14. Cattoretti G, Becker MHG, Key G: Monoclonal antibodies against recombinant parts of the KI-67 anigen (MIB1 and MIB3) detet proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168: 357–363, 1992
    Google Scholar
  15. Enestrom S, Vavruch L, Franlund B: Ki-67 antigen expression as a prognostic factor inprimary and recurrent astrocytomas. Neuro-Chirurgie 44: 25–30, 1998
    Google Scholar
  16. Coffin CM, Braun JT, Wick MR: A clinicopathologic and immunohistochemical analysis of 53 cases of medulloblastoma with emphasis of synaptophysin expression. Mod Pathol 3: 164–170, 1990
    Google Scholar
  17. Herpers MJHM, Budka H: Primitive neuroectodermal tumors including the medulloblastoma: glial differentiation signaled by immunoreactivity for GFAP is restricted to the prue desmoplastic medulloblastoma ('arachnoidal sarcoma of the cerebellum'). Clin Neuropathol 4: 12–18, 1985
    Google Scholar
  18. Kumanishi T, Washiyama K, Watabe K: Glial fibrillary acidic protein in medulloblastoma. Acta Neuropathologica 67: 1–5, 1985
    Google Scholar
  19. Maraziotis T, Perentes E, Karamitopoulow E, Nakagawa Y: Neuron-associated class III beta-tubulin isotype, retinal S-antigen, synaptophysin, and glial fibrillary acidic protein in human medulloblastomas: a clinicopathologic analysis of 37 cases. Acta Neuropathologica 84: 355–363, 1992
    Google Scholar
  20. Goldberg-Stern H, Gadoth N, Stern S: The prognostic significance of glial fibrillary acidic protein staining in medulloblastoma. Cancer 68: 568–573, 1991
    Google Scholar
  21. Packer RJ, Sutton LN, Rorke LB, Littman PA: Prognostic importance of cellular differentiation in medulloblastoma of childhood. J Neurosurg 61: 296–301, 1984
    Google Scholar
  22. Batra SK, McLendon RE, Koo JS, Castelino-Prabhu S, Fuchs HE, Krischer JP, Friedman HS, Bigner DD, Bigner SH: Prognostic implications of chromosome 17p deletions in human medulloblastomas. J Neuro-Oncol 24: 39–45, 1995
    Google Scholar
  23. Scheurlen WG, Schwabe GC, Joos S, Mollenhauer J, Sorensen N, Kuhl J: Molecular analyses of childhood primitive neuroectodermal tumors defines markers associated with poor outcome. J Clin Oncol 16: 2478–2485, 1998
    Google Scholar
  24. Zerbini C, Gelber RD, Weinberg D, Sallan SE, Barnes P, Kupsky W, Scott MR, Tarbell NJ: Prognostic factors in medulloblastoma, including DNA ploidy. J Clin Oncol 11: 616–622, 1993
    Google Scholar
  25. Levine AJ, Momand J, Finlay C: The p53 tumor suppressor gene. Nature 351: 453–465, 1991
    Google Scholar
  26. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD: Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70: 923–935, 1992
    Google Scholar
  27. Finley CA, Hinds PW, Levine AJ: The p53 Proto-oncogene can act as a suppressor of transformation. Cell 57: 1083–1093, 1989
    Google Scholar
  28. Sabbatini P, Lin J, Levine AJ, White E: Essential role for p53-mediated transcription in E1A-induced apoptosis. Genes and Development 9: 2184–2192, 1995
    Google Scholar
  29. Reich NC, Oren M, Levine AJ: Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol Cellular Biol 3(12): 2143–2150, 1983
    Google Scholar
  30. Hinds PW, Finlay CA, Quartin RS, Baker SJ, Fearon ER, Vogelstein B, Levine AJ: Mutant p53 DNA clones from human colon carcinomas cooperated with ras in transforming primary rat cells: a comparison of the ‘hot spot’ mutant phenotypes. Cell Growth Differentiation 1: 571–580, 1990
    Google Scholar
  31. Ambros RA, Ross JS, Kallakury BVS, Malfetano J, Kim Y, Hwang J, Breese K, Figge J: p53 gene satus in endometial carcinoma showing diffuse positivity for p53 protein by immunohistochemial analysis. Mod Pathol 8: 441–445, 1995
    Google Scholar
  32. Ono Y, Tamiya T, Ichikawa T, Matsumoto K, Furuta T, Ohmoto T, Akiyama K, Seki S, Ueki K, Louis DN: Accumulation of wild-type p53 in astrocytoms is associated with increased p21 expression. Acta Neuropathol 94: 21–27, 1997
    Google Scholar

Download references